Antispasmodic
Adult: 40-80 mg tid.
Child: 1-6 years 20-40 mg 2-3 times daily; >6 years 40 mg tid.
Child: 1-6 years 20-40 mg 2-3 times daily; >6 years 40 mg tid.
Indications and Dosage
Oral
Antispasmodic Adult: 40-80 mg tid.
Child: 1-6 years 20-40 mg 2-3 times daily; >6 years 40 mg tid. |
Administration
May be taken with or without food.
|
Special Precautions
Patient with cardiac dysfunction. Renal and hepatic impairment. Children. Pregnancy and lactation.
|
Adverse Reactions
Cardiac disorders: Palpitation.
Gastrointestinal disorders: Gastrointestinal disturbance, nausea, vomiting, constipation, dry mouth. Nervous system disorders: Vertigo, headache, dizziness. Psychiatric disorders: Insomnia. Vascular disorders: Orthostatic hypotension. |
Patient Counseling Information
This drug may occasionally cause vertigo, if affected, do not drive or operate machinery.
|
Overdosage
Symptoms: Drowsiness, hypotension, and reduced gastric motility. Management: Symptomatic and supportive treatment.
|
Drug Interactions
May attenuate the antiparkinsonian action of levodopa.
|
Action
Description:
Mechanism of Action: Drotaverine is a musculotropic antispasmodic agent which inhibits phosphodiesterase enzyme, causing increased cAMP levels thereby producing smooth muscle relaxation. |
Chemical Structure
|
Storage
Store below 30°C. Protect from light.
|
MIMS Class
|
ATC Classification
A03AD02 - drotaverine ; Belongs to the class of papaverine and derivatives. Used in the treatment of functional bowel disorders.
|
References
Buckingham R (ed). Drotaverine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 25/09/2023. Deolin (Unison). MIMS Thailand. http://www.mims.com/thailand. Accessed 25/09/2023. Spamodyn (Noripharma Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 25/09/2023.
|